Medpace Holdings Inc (MEDP) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Medpace Holdings Inc stock (MEDP) is currently trading at $466.80. Medpace Holdings Inc PE ratio is 30.11. Medpace Holdings Inc PS ratio (Price-to-Sales) is 5.17. Analyst consensus price target for MEDP is $489.69. WallStSmart rates MEDP as Moderate Buy.
- MEDP PE ratio analysis and historical PE chart
- MEDP PS ratio (Price-to-Sales) history and trend
- MEDP intrinsic value — DCF, Graham Number, EPV models
- MEDP stock price prediction 2025 2026 2027 2028 2029 2030
- MEDP fair value vs current price
- MEDP insider transactions and insider buying
- Is MEDP undervalued or overvalued?
- Medpace Holdings Inc financial analysis — revenue, earnings, cash flow
- MEDP Piotroski F-Score and Altman Z-Score
- MEDP analyst price target and Smart Rating
Medpace Holdings Inc
📊 No data available
Try selecting a different time range
MEDP Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Medpace Holdings Inc (MEDP)
MEDP trades at a significant discount to its Graham intrinsic value of $716.04, offering a 41% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Medpace Holdings Inc (MEDP) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, return on equity, operating margin. Concerns around price/book. Overall metrics suggest strong investment potential with favorable risk/reward.
Medpace Holdings Inc (MEDP) Key Strengths (7)
Every $100 of shareholder equity generates $70 in profit
Revenue surging 32.00% year-over-year
86.27% of shares held by major funds and institutions
Large-cap company with substantial market presence
Strong operational efficiency: $22 kept per $100 revenue
Strong earnings growth at 26.90% per year
Strong profitability: $18 kept per $100 revenue
Medpace Holdings Inc (MEDP) Areas to Watch (3)
Very expensive at 28.0x book value
Paying a premium for growth, expensive relative to earnings expansion
Premium valuation at 5.2x annual revenue
Supporting Valuation Data
Medpace Holdings Inc (MEDP) Detailed Analysis Report
Overall Assessment
This company scores 70/100 in our Smart Analysis, earning a B- grade. Out of 10 metrics analyzed, 7 register as strengths (avg 9.0/10) while 3 fall into concern territory (avg 3.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Revenue Growth, Institutional Own.. Profitability is solid with Return on Equity at 70.20%, Operating Margin at 21.60%, Profit Margin at 17.80%. Growth metrics are encouraging with Revenue Growth at 32.00%, EPS Growth at 26.90%.
The Bear Case
The primary concerns are Price/Book, PEG Ratio, Price/Sales. Some valuation metrics including PEG Ratio (2.25), Price/Sales (5.17), Price/Book (27.98) suggest expensive pricing.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Book improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 70.20% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 32.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
The combination of Return on Equity and Revenue Growth makes a compelling case at current levels. The key risk is Price/Book, but the overall fundamental picture is positive with a clear path to maintaining or improving the current B- grade.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
MEDP Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
MEDP's Price-to-Sales ratio of 5.17x trades at a 26% premium to its historical average of 4.11x (75th percentile). The current valuation is 35% below its historical high of 7.97x set in Nov 2025, and 184% above its historical low of 1.82x in May 2017. Over the past 12 months, the PS ratio has expanded from ~4.2x, reflecting growing market expectations outpacing revenue growth.
Compare MEDP with Competitors
Top DIAGNOSTICS & RESEARCH stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Medpace Holdings Inc (MEDP) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
Medpace Holdings Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 2.5B with 32% growth year-over-year. Profit margins of 17.8% are healthy, with room for further expansion as the business scales.
Key Findings
Revenue growing at 32% YoY, reaching 2.5B. This pace significantly outperforms most DIAGNOSTICS & RESEARCH peers.
ROE of 70.2% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Growth sustainability: can Medpace Holdings Inc maintain 32%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact Medpace Holdings Inc.
Bottom Line
Medpace Holdings Inc offers an attractive blend of growth (32% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Medpace Holdings Inc(MEDP)
NASDAQ
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company is headquartered in Cincinnati, Ohio.